Literature DB >> 9876597

Cyclodextrin solubilization of ETH-615, a zwitterionic drug.

T Loftsson1, D S Petersen.   

Abstract

Therapeutic usefulness of many zwitterionic drugs is hampered by their very low aqueous solubility. The purpose of this work was to investigate the effects of cyclodextrins on the solubility of the zwitterionic drug ETH-615, the role that charge might play in the cyclodextrin complexation, and the influence of polymers and ion-pairing agents on the cyclodextrin solubilization. The effects of five different beta-cyclodextrin derivatives were evaluated, i.e., the anionic beta-cyclodextrin sulfobutyl ether sodium salt and carboxymethyl-beta-cyclodextrin sodium salt, the uncharged 2-hydroxypropyl-beta-cyclodextrin and randomly methylated beta-cyclodextrin, and the cationic 2-hydroxy-3-trimethyl-ammoniopropyl-beta-cyclodextrin. The uncharged cyclodextrins had much larger solubilizing effect on ETH-615 than the charged ones. However, due to the highly polar zwitterionic structure of ETH-615 the stability constants of its cyclodextrin complexes were several orders of magnitude smaller than those commonly observed for uncharged lipophilic compounds. Cyclodextrin solubilization of ETH-615 was enhanced by water-soluble polymers and ion-pairing agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876597     DOI: 10.3109/03639049809085632

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  3 in total

1.  Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone.

Authors:  Indranil Nandi; Michelle Bateson; Mohammad Bari; Hemant N Joshi
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

Review 2.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

3.  The role of difluprednate ophthalmic emulsion in clinical practice.

Authors:  Karim N Jamal; David G Callanan
Journal:  Clin Ophthalmol       Date:  2009-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.